Market advancements are driven by rising incidences of neuroendocrine tumors, improved diagnostics, and targeted therapies. Key players like Novartis AG and Pfizer Inc. are investing in innovative ...

driven by multinational pharmaceutical names like Novartis and Hoffmann-La Roche, which invest billions in R&D each year to pioneer new medicines. Last but not least, Switzerland’s high-tech ...